``I surprised anyone has written a prescription for Nexium.
It was not stopped because trial results did not find increased risk in the first 18 months of the trial, the FDA.
The FDA safety in charge of the report David Graham concluded Vioxx posed than the other major drug in its class Celebrex.
' I gave her the facts,'' he.
I couldn't see Merck saying we're going to market a drug with a safety problem.